{"disease":{"id":"her2-positive-breast-carcinoma","name":"her2 positive breast carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06058377","title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":3680,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT00005970","title":"Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3436,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01275677","title":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3270,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04379570","title":"Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1167,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT04457596","title":"T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1056,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT00785291","title":"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":799,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07030569","title":"RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT03418961","title":"S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":491,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT06112613","title":"Mobile Health for Adherence in Breast Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":410,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT04569747","title":"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":393,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT07136493","title":"Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer","phase":"NA","overall_status":"SUSPENDED","enrollment_count":350,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT02003209","title":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":315,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03500380","title":"A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":301,"lead_sponsor_name":"RemeGen Co., Ltd.","has_results":false},{"nct_id":"NCT03908749","title":"A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Positive Her-2","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT00390455","title":"Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05194072","title":"A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":250,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT05710328","title":"Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":235,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT04517838","title":"Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":230,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03199885","title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":190,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04802876","title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"SOLTI Breast Cancer Research Group","has_results":false},{"nct_id":"NCT06534125","title":"Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT01622868","title":"Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03251378","title":"A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":true},{"nct_id":"NCT05868226","title":"PRE-I-SPY Phase I/Ib Oncology Platform Program","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT06714617","title":"Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT02945579","title":"Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07407920","title":"Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04450732","title":"Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":96,"lead_sponsor_name":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT06557057","title":"Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk","phase":"","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00684983","title":"Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05795101","title":"TRUDI: TDXD+Durva in HER2+/Low IBC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":63,"lead_sponsor_name":"Filipa Lynce, MD","has_results":false},{"nct_id":"NCT01730833","title":"Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":63,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT01327781","title":"Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":62,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06179303","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT05327608","title":"Neoadjuvant Breast Cancer Time Restricted Eating","phase":"NA","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT03530696","title":"T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"University of Arizona","has_results":true},{"nct_id":"NCT04704661","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":51,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06868758","title":"Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Chongqing General Hospital","has_results":false},{"nct_id":"NCT03602079","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT04660929","title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Carisma Therapeutics Inc","has_results":false},{"nct_id":"NCT03368729","title":"Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT02957968","title":"Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"Virginia Commonwealth University","has_results":true},{"nct_id":"NCT03319459","title":"FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT07112053","title":"A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT05464810","title":"Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT01434303","title":"Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03841110","title":"FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT02152943","title":"Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}